#News for #Investors and #Media
China’s National Medical Products Administration (NMPA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: gsk.to/3QPIamj
#News for #investors and #media: Today we announced the completion of our acquisition of 35Pharma Inc., adding to our Respiratory, Immunology & Inflammation pipeline.
Find out more: gsk.to/4ccpQw3
#News for #Investors and #Media: Today at #SGO2026, we’re presenting new data on an investigational antibody-drug conjugate from our oncology pipeline.
Learn more: gsk.to/3Q00jh7
We're at #SGO26!
With an innovative pipeline, we’re building on our strong foundations in oncology research to improve how people live with cancer 🧡
Join us as we share more about our vision for transforming cancer care.
🔗 Learn more: bit.ly/4dz0866
How do ADCs work?
Antibody-drug conjugates (ADCs) seek out cancer cells within the body.
ADC binds to the antigen on the cancerous cell. The ADC is absorbed into the cancerous cell.
Enzymes inside the cell break down the ADC linker and release the payload/drug to kill the cancerous cell.
Antibody-drug conjugates (ADCs) - what exactly are they?
➡️ Swipe to find out how this innovation technology works to target cancer cells.
🔗 And dive deeper into the world of ADCs in our latest Behind the Science article: bit.ly/41kHkjL
#News for #Media and #Investors:
China's National Medical Products Administration (NMPA) has approved our new therapy for people living with chronic rhinosinusitis with nasal polyps (CRSwNP).
For more information, visit: bit.ly/43sHkQ0
The UK-US deal on pharmaceuticals is now finalised.
The UK-US deal on pharmaceuticals is now finalised, an important step for UK life sciences.
Read our short statement ⤵️
#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review in China.
Learn more: gsk.to/4uZos7p
#News for #Media and #Investors: China’s National Medical Products Administration (NMPA) has approved our new therapy for the treatment of severe asthma.
For more information, visit: gsk.to/47tXAlQ
#News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review by the EMA.
Learn more: gsk.to/489nuvm
#News for #Investors and #Media: Today we announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more: gsk.to/4sZtdvP
#News for #investors and #media: Today, we are announcing that one of our liver medicines has been approved by the US Food and Drug Administration (FDA).
Find out more: gsk.to/4bHlfke
RSV science image
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the US Food and Drug Administration (FDA).
Learn more: gsk.to/4uHdPpM
#Investors and #Media
Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures in our 2025 Annual Report. CER% represents constant exchange rates. AER% represents actual exchange rates. $GSK
For investors: bit.ly/4d1ASoz
Published today, our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders.
Take a look at the highlights ⤵️
🔗 Investors and media can read more: gsk.to/4rTabHu
Today we’re at #SLEuro discussing the importance of early intervention and its role in reducing the risk of organ damage progression for patients with lupus and lupus nephritis.
#News for #investors and #media: Today we announced the completion of our acquisition of RAPT Therapeutics, adding to our growing Respiratory, Immunology & Inflammation (RI&I) pipeline.
Find out more: gsk.to/4bjpC5H
City scape shot of Philadelphia
We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more 🫁
#News for #investors and #media: Today we are announcing our potential treatment for chronic hepatitis B has been accepted for regulatory review in Japan.
Learn more: gsk.to/3MKpqTS
News for #Investors and #Media:
Today at #CROI2026, our specialist HIV company ViiV Healthcare, presented new insights on our investigational long-acting therapies.
🔗 Find out more on our website: gsk.to/4sfUv0S
#News for #investors and #media: We’ve announced an agreement to acquire 35Pharma.
Find out more: gsk.to/3ZS9thp
News for #Investors and #Media:
New data published in the New England Journal of Medicine compare efficacy of different forms of HIV treatment for people with adherence challenges.
🔗 Find out more on our website: gsk.to/40fqNNh
#News for #Investors and #Media: Today we are presenting new data about one of our vaccines.
Learn more: gsk.to/4bZNQ66
#News for #investors and #media: The European Commission has approved our new therapy to treat two respiratory diseases.
Learn more here: gsk.to/4tzOptr
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration.
Learn more: gsk.to/4qnf6Pd
Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.
#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD).
Learn more here: gsk.to/3O0TpXN
#Investors and #Media Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK For investors: www.gsk.com/en-gb/invest...
Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks.
Hear more from our CEO Luke Miels ⤵️
More information for media and investors: gsk.to/4r7A5qv $GSK #earnings
Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs
